Celldex Therapeutics, Inc. $CLDX Shares Bought by TSP Capital Management Group LLC

TSP Capital Management Group LLC boosted its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 10.6% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 371,427 shares of the biopharmaceutical company’s stock after buying an additional 35,450 shares during the quarter. Celldex Therapeutics accounts for about 2.4% of TSP Capital Management Group LLC’s holdings, making the stock its 19th biggest holding. TSP Capital Management Group LLC owned approximately 0.56% of Celldex Therapeutics worth $7,559,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Celldex Therapeutics in the first quarter valued at $269,000. GSA Capital Partners LLP acquired a new position in Celldex Therapeutics during the 1st quarter worth about $1,131,000. Vanguard Group Inc. boosted its holdings in Celldex Therapeutics by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 3,898,435 shares of the biopharmaceutical company’s stock valued at $70,757,000 after acquiring an additional 16,440 shares during the period. Deutsche Bank AG grew its position in Celldex Therapeutics by 13.8% in the 1st quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company’s stock valued at $2,510,000 after acquiring an additional 16,788 shares in the last quarter. Finally, Invesco Ltd. grew its position in Celldex Therapeutics by 24.6% in the 1st quarter. Invesco Ltd. now owns 52,443 shares of the biopharmaceutical company’s stock valued at $952,000 after acquiring an additional 10,342 shares in the last quarter.

Celldex Therapeutics Stock Down 1.6%

NASDAQ:CLDX opened at $25.58 on Wednesday. The company has a market capitalization of $1.70 billion, a PE ratio of -8.50 and a beta of 1.36. The stock’s 50 day moving average price is $25.64 and its 200 day moving average price is $22.95. Celldex Therapeutics, Inc. has a 52-week low of $14.40 and a 52-week high of $29.05.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Monday, November 10th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.13). Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. As a group, sell-side analysts anticipate that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on CLDX. Mizuho began coverage on shares of Celldex Therapeutics in a research report on Tuesday, October 21st. They set an “outperform” rating and a $48.00 price target on the stock. HC Wainwright cut their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a research report on Wednesday, October 8th. Barclays cut their price target on Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating on the stock in a report on Tuesday, November 11th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $62.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Celldex Therapeutics has an average rating of “Moderate Buy” and an average target price of $43.80.

Insider Activity

In related news, insider Richard M. Wright sold 49,298 shares of the business’s stock in a transaction dated Thursday, November 13th. The stock was sold at an average price of $24.00, for a total value of $1,183,152.00. Following the transaction, the insider owned 20,833 shares in the company, valued at $499,992. The trade was a 70.29% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.40% of the stock is currently owned by corporate insiders.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.